Lukehart S A, Baker-Zander S A
Antimicrob Agents Chemother. 1987 Feb;31(2):187-90. doi: 10.1128/AAC.31.2.187.
Roxithromycin (RU 965), a new macrolide antibiotic, was shown to be effective for therapy of active syphilis in rabbits. Dark-field-positive lesions were produced in adult male rabbits by intradermal inoculation of approximately 10(6) Treponema pallidum organisms at each of 11 sites. Beginning 7 days after infection, six animals per group were treated with benzathine penicillin G (200,000 U, intramuscularly, weekly for 2 weeks) or roxithromycin (15 mg/kg of body weight, orally, twice daily for 15 days); six animals were not treated. Chancres in untreated animals were dark-field positive throughout the 16-day observation period; all benzathine penicillin-treated rabbits were dark-field negative 1 day after the initiation of therapy. Five of six animals treated with roxithromycin were dark-field negative on day 3 following the initiation of therapy; the sixth animal was dark-field negative by day 6. Lesions in untreated animals reached a mean (+/- standard deviation) maximum diameter of 14.7 +/- 1.91 mm compared with 8.4 +/- 3.6 mm for benzathine penicillin-treated (P less than 0.005) and 10.4 +/- 1.2 mm for roxithromycin-treated (P less than 0.001) animals. Ulceration occurred at 62 of 66 lesions in untreated animals compared with 0 of 66 lesions in each treated group. At 3, 6, and 12 weeks postinfection, Venereal Disease Research Laboratory antibody titers were significantly higher (P less than 0.05) in untreated than in treated animals. Titers in penicillin-treated versus roxithromycin-treated animals were significantly different at 6 weeks postinfection but not at 3 and 12 weeks postinfection. Transfer of tissue from treated rabbits to seronegative recipient animals did not reveal any evidence of persistent infection in the benzathine penicillin- or roxithromycin-treated animals. These findings indicate that benzathine penicillin and roxithromycin, at the doses indicated above, are effective in treating active syphilis in rabbit model.
罗红霉素(RU 965)是一种新型大环内酯类抗生素,已证明对兔梅毒活动期的治疗有效。通过在成年雄性兔的11个部位皮内接种约10⁶梅毒螺旋体,产生暗视野阳性病变。感染7天后,每组6只动物分别用苄星青霉素G(200,000 U,肌肉注射,每周1次,共2周)或罗红霉素(15 mg/kg体重,口服,每日2次,共15天)治疗;6只动物未治疗。未治疗动物的溃疡在整个16天观察期内暗视野均为阳性;所有苄星青霉素治疗的兔在治疗开始后1天暗视野转为阴性。6只接受罗红霉素治疗的动物中有5只在治疗开始后第3天暗视野转为阴性;第6只动物在第6天暗视野转为阴性。未治疗动物病变的平均(±标准差)最大直径为14.7±1.91 mm,苄星青霉素治疗的动物为8.4±3.6 mm(P<0.005),罗红霉素治疗的动物为10.4±1.2 mm(P<0.001)。未治疗动物的66个病变中有62个发生溃疡,而每个治疗组的66个病变均未发生溃疡。感染后3、6和12周,未治疗动物的性病研究实验室抗体滴度显著高于治疗动物(P<0.05)。感染后6周时,青霉素治疗组与罗红霉素治疗组的滴度有显著差异,但在感染后3周和12周时无显著差异。将治疗兔的组织转移至血清阴性的受体动物后,未发现苄星青霉素或罗红霉素治疗的动物有持续感染的迹象。这些发现表明,上述剂量的苄星青霉素和罗红霉素对兔梅毒活动期模型的治疗有效。